Allarity Therapeutics, Inc.
ALLR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALLR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALLR
Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer and relapsed small cell lung cancer, with a recent $20 million financing extending cash runway into mid-2028.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Allarity Therapeutics, Inc..
Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer and relapsed small cell lung cancer, with a recent $20 million financing extending cash runway into mid-2028.
- Allarity is focused on developing stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer (FDA Fast Track designation) and relapsed small cell lung cancer [news · 2026-05-15].
- As of June 30, 2026, the company reported cash and equivalents of $26.9M, zero revenue, a net loss of $3.4M, shareholders' equity of $12.2M, and total debt of $20.9M [sec].
- A $20 million non-convertible debt financing closed in March 2026 is expected to fund completion of the Phase 2 ovarian cancer trial and extend cash runway into mid-2028 [news · 2026-03-06].
- Enrollment opened in February 2026 for a Phase 2 trial of stenoparib plus temozolomide in relapsed small cell lung cancer, with first patients dosed that same month [sec · filed 2026-02-04] [sec · filed 2026-02-19].
- Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP® companion diagnostic [news · 2026-05-15].
What works
- Stenoparib has received FDA Fast Track designation for advanced ovarian cancer, which may expedite development and review [news · 2025-11-14].
- The company reported landmark median overall survival exceeding 25 months in its ongoing Phase 2 trial for advanced ovarian cancer [news · 2025-11-14].
- A $20 million non-convertible debt financing closed in March 2026 is expected to fund completion of the Phase 2 ovarian cancer trial and extend cash runway into mid-2028 [news · 2026-03-06].
- Allarity has secured a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP® companion diagnostic, potentially strengthening its competitive position [news · 2026-05-15].
What to weigh
- The company has recorded very limited revenue since inception and has an accumulated deficit, reflecting a history of operating losses [sec_mda · as of 2026-03-30].
- As of June 30, 2026, total debt of $20.9M exceeded shareholders' equity of $12.2M, indicating a leveraged balance sheet [sec].
- Two prior clinical trials (Phase 2 for ixabepilone and Phase 1 for 2X-121 monotherapy) were terminated, highlighting clinical development risks [catalyst].
- The company is dependent on successful clinical outcomes and regulatory approvals for stenoparib, with no approved products generating revenue [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
Enrollment opened for Phase 2 trial of stenoparib plus temozolomide in relapsed small cell lung cancer
“enrollment has opened for its new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer”
SEC filings · February 4, 2026
First patients dosed in the VA-funded Phase 2 trial for relapsed small cell lung cancer
“the first patients have been dosed with stenoparib and temozolomide in the VA-funded investigator-initiated Phase 2 trial for the treatment of relapsed small cell lung cancer”
SEC filings · February 19, 2026
FDA Fast Track designation for stenoparib in advanced ovarian cancer
“Received FDA Fast Track designation for stenoparib in advanced ovarian cancer”
News · November 14, 2025
Cash and restricted cash of approximately $29.8 million as of March 31, 2026
“Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026”
News · May 15, 2026
Catalyst timeline
- 2026-04-01 · Earnings Report - SEC 8-K filing — Quarterly financial results and business update expected.
- 2026-04-22 · AACR Conference Presentation — Allarity presented data at the AACR meeting; potential for new clinical or preclinical updates.
- 2026-06-18 · ESMO Gynaecological Cancers Congress 2026 — Trial-in-Progress poster on Phase 2 stenoparib trial presented; may provide enrollment or design insights.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Stenoparib is in Phase 2 trials; prior trials for other candidates were terminated, and positive results are not guaranteed [catalyst].
- No approved products or revenue — Allarity has recorded very limited revenue since inception and relies on financing to fund operations [sec_mda · as of 2026-03-30].
- High debt relative to equity — As of June 30, 2026, total debt of $20.9M exceeded shareholders' equity of $12.2M, indicating financial leverage [sec].
- Dependence on single drug candidate — Allarity's pipeline is concentrated on stenoparib; any setback could materially impact the company [news · 2026-05-15].
What to watch
- Completion of stenoparib active pharmaceutical ingredient manufacturing, expected no later than Q3 2026 [news · 2026-05-06].
- Data readouts from the Phase 2 trial of stenoparib plus temozolomide in relapsed small cell lung cancer [sec · filed 2026-02-19].
- Progress of the Phase 2 ovarian cancer trial, including any updates on median overall survival [news · 2025-11-14].
- Cash runway and potential need for additional financing beyond the current mid-2028 projection [news · 2026-03-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Allarity Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Allarity Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
33.2 months
D/E 8.08
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$1.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 343,590 | $375K |
| renaissance technologies llc | 228,084 | $249K |
| geode capital management, llc | 190,393 | $208K |
| state street corp | 137,600 | $150K |
| vanguard fiduciary trust co | 74,913 | $82K |
| northern trust corp | 48,103 | $52K |
| xtx topco ltd | 28,967 | $32K |
| two sigma investments, lp | 27,492 | $30K |
| two sigma securities, llc | 12,334 | $13K |
| citigroup inc | 7,766 | $8K |
Showing top 10 of 13 institutional holders of Allarity Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 2.2%
- Days to cover
- 2.0
- Shares short
- 353,879
- Daily short volume (May 20, 2026)
- 65.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALLR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Allarity Therapeutics, Inc.?
Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer and relapsed small cell lung cancer, with a recent $20 million financing extending cash runway into mid-2028.
What is Allarity Therapeutics, Inc.'s lead drug candidate?
Allarity Therapeutics, Inc.'s most advanced tracked candidate is stenoparib (Phase 2) for Advanced, recurrent ovarian cancer; Platinum resistant or platinum ineligible ovarian cancer (PROC); Relapsed Small Cell Lung Cancer (SCLC).
Who is the CEO of Allarity Therapeutics, Inc.?
Mr. Thomas H. Jensen is the chief executive officer of Allarity Therapeutics, Inc. (ALLR).
Where is Allarity Therapeutics, Inc. headquartered?
Allarity Therapeutics, Inc. (ALLR) is headquartered in Tarpon Springs, FL, United States.
What therapeutic areas does Allarity Therapeutics, Inc. focus on?
Allarity Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.